Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
Cefazolin vs ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Cefazolin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidation and disrupting peptidoglycan cross-linking. This leads to cell lysis and death primarily in susceptible gram-positive bacteria.
Cefazolin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and disrupting peptidoglycan cross-linking. This leads to cell lysis and death, primarily in actively dividing bacteria.
Perioperative prophylaxis (surgical prophylaxis),Respiratory tract infections,Urinary tract infections,Skin and soft tissue infections,Biliary tract infections,Bone and joint infections,Genital infections,Septicemia,Endocarditis (off-label)
Perioperative prophylaxis,Respiratory tract infections,Urinary tract infections,Skin and soft tissue infections,Biliary tract infections,Bone and joint infections,Septicemia,Endocarditis,Genital infections (e.g., prostatitis, epididymitis),Off-label: Surgical prophylaxis in certain procedures
1-2 g IV/IM every 6-8 hours; maximum 12 g/day.
For uncomplicated infections: 1-2 g IV every 8 hours. For severe infections: up to 2 g IV every 4 hours. Administered as an IV infusion over 30-60 minutes.
1.8 hours in normal renal function; extends to 30–70 hours in end-stage renal disease (Cr Cl <10 m L/min).
1.8 hours (normal renal function); prolonged to 10-30 hours in severe renal impairment (Cr Cl <10 m L/min)
Cefazolin undergoes minimal hepatic metabolism; it is primarily excreted unchanged in the urine via glomerular filtration and tubular secretion. The drug is not significantly metabolized by the liver.
Cefazolin is minimally metabolized; primarily undergoes renal tubular secretion and glomerular filtration. Not significantly metabolized by cytochrome P450 enzymes.
Renal: 80–90% unchanged via glomerular filtration and tubular secretion; biliary: <1%; fecal: negligible.
Renal: >80% unchanged via glomerular filtration and tubular secretion; biliary/fecal: <1%
80% bound to albumin.
80-86% bound to serum albumin
0.12–0.14 L/kg; approximates extracellular fluid volume, indicating low tissue penetration.
0.12-0.16 L/kg; primarily in extracellular fluid
Intramuscular: 100% (complete absorption).
IM: ~85% (peak levels in 0.5-2 hours); IV: 100%
Cr Cl >55 m L/min: no adjustment; Cr Cl 35-54 m L/min: 1-2 g every 8 hours; Cr Cl 11-34 m L/min: 500 mg-1 g every 12 hours; Cr Cl ≤10 m L/min: 500 mg-1 g every 24-48 hours.
Cr Cl 35-54 m L/min: 1-2 g every 8 hours. Cr Cl 11-34 m L/min: 1-2 g every 12 hours. Cr Cl <10 m L/min: 1-2 g every 24-48 hours. For patients on hemodialysis, administer 1-2 g after each dialysis session.
No dosage adjustment required for hepatic impairment.
No dosage adjustment required for hepatic impairment. Cefazolin is primarily renally eliminated.
50-100 mg/kg/day IV/IM divided every 8 hours; severe infections: 100 mg/kg/day divided every 6-8 hours.
For children >1 month: 25-100 mg/kg/day IV divided every 6-8 hours. For severe infections: up to 100 mg/kg/day IV divided every 6-8 hours. Maximum dose: 6 g/day.
No specific adjustment based solely on age; dose adjustment based on renal function per Cr Cl.
Adjust dose based on renal function. Calculate Cr Cl and follow renal adjustment guidelines. No additional geriatric-specific modifications beyond renal consideration.
No FDA black box warning.
None
Hypersensitivity reactions (including anaphylaxis) may occur; cross-allergenicity among cephalosporins and penicillins is possible.,Clostridioides difficile-associated diarrhea (CDAD) can occur with antibiotic use.,Dosage adjustment required in patients with renal impairment due to predominantly renal elimination.,Prolonged use may result in overgrowth of nonsusceptible organisms (e.g., Candida, Pseudomonas).,Seizures may occur with high doses, especially in patients with renal impairment.
Hypersensitivity reactions: Cross-allergenicity with other beta-lactams; caution in penicillin-allergic patients,Acute generalized exanthematous pustulosis (AGEP),Clostridioides difficile-associated diarrhea (CDAD),Seizures at high doses or in renal impairment,Nephrotoxicity (especially with aminoglycosides or loop diuretics),Hemolytic anemia (rare),Interference with glucose and protein tests,Use in renal impairment: dose adjustment required,Pregnancy category B: use only if clearly needed,Geriatric use: increased risk of adverse effects
Known hypersensitivity to cefazolin or any cephalosporin antibiotic,Immediate-type hypersensitivity reaction to penicillins (relative caution due to potential cross-allergenicity)
Hypersensitivity to cefazolin or any cephalosporin,Severe immediate hypersensitivity (e.g., anaphylaxis) to penicillins or other beta-lactams
No significant food interactions. Alcohol should be avoided during treatment and for at least 72 hours after last dose due to potential disulfiram-like reaction (nausea, vomiting, flushing).
No specific food interactions. Avoid alcohol during therapy and for 72 hours post-treatment due to risk of disulfiram-like reaction (cefazolin has a methylthiotetrazole side chain). Patients with diabetes should account for dextrose content (5 g/100 m L) in their carbohydrate intake.
Cefazolin is classified as FDA Pregnancy Category B. Animal studies have not demonstrated fetal risk, and adequate, well-controlled studies in pregnant women are lacking. Generally considered safe throughout pregnancy; no known teratogenic effects in the first trimester. Use only if clearly needed.
Pregnancy Category B. No evidence of risk in humans based on animal studies and human data; however, adequate studies in pregnant women are lacking. No known teratogenic effects in first trimester; use only if clearly needed.
Cefazolin is excreted into breast milk in low concentrations (M/P ratio approximately 0.02–0.05). It is considered compatible with breastfeeding; potential for infant gut flora alteration but unlikely to cause adverse effects. Use caution in neonates with hyperbilirubinemia or glucose-6-phosphate dehydrogenase deficiency.
Cefazolin is excreted into breast milk in low concentrations (M/P ratio approximately 0.2-0.5). Considered compatible with breastfeeding; monitor for potential gastrointestinal effects in the infant.
Pregnancy increases volume of distribution and renal clearance, potentially lowering serum concentrations. Standard dosing (1–2 g every 8 hours for most infections) is generally adequate; for serious infections, consider higher doses (up to 12 g/day) or more frequent intervals (every 6 hours) in the third trimester. Adjust based on therapeutic response and renal function.
Increased glomerular filtration rate during pregnancy may require higher doses or more frequent dosing to achieve therapeutic concentrations; specific dose adjustment not established; monitor clinical response.
Cefazolin is a first-generation cephalosporin with a short half-life; requires dose adjustment in renal impairment. Watch for cross-allergenicity in penicillin-allergic patients (approx. 10% risk). Administer parenterally only; no oral formulation available. Common surgical prophylaxis antibiotic due to good coverage of skin flora.
For surgical prophylaxis, administer within 60 minutes before incision. Use extended infusion (over 1-2 hours) for critically ill patients to optimize pharmacokinetic/pharmacodynamic target attainment. Monitor renal function given cefazolin excretion; adjust dose for Cr Cl <55 m L/min. Avoid in patients with immediate-type hypersensitivity to penicillins (10% cross-reactivity risk). In obese patients (BMI ≥40 kg/m²), consider doubling the standard dose (2 g IV) for adequate tissue penetration.
This medication is given by injection or IV, not by mouth.,Report any signs of allergic reaction: rash, hives, itching, difficulty breathing.,May cause diarrhea; notify your doctor if severe or persistent.,Avoid alcohol while taking this medication to prevent disulfiram-like reaction.,Complete the full course as prescribed even if you feel better.
Complete the full course of antibiotics as prescribed, even if you feel better.,Report any signs of allergic reaction (rash, itching, difficulty breathing, swelling of face or throat) to your healthcare provider immediately.,If you are diabetic, note that each 1% dextrose solution provides 3.4 kcal/g; monitor blood glucose levels closely.,The medication is given intravenously; ensure the IV site is clean and free from redness, swelling, or pain.,Avoid alcohol during treatment and for at least 72 hours after the last dose to prevent disulfiram-like reactions (flushing, nausea, vomiting).
"Phenprocoumon may increase the anticoagulant activities of Cefazolin."
"Warfarin may increase the anticoagulant activities of Cefazolin."
"The protein binding of Cefazolin can be decreased when combined with Phenytoin."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about Cefazolin vs ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER, answered by our medical review team.
Cefazolin is a Cephalosporin Antibiotic that works by Cefazolin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidation and disrupting peptidoglycan cross-linking. This leads to cell lysis and death primarily in susceptible gram-positive bacteria.. ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER is a Cephalosporin Antibiotic that works by Cefazolin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and disrupting peptidoglycan cross-linking. This leads to cell lysis and death, primarily in actively dividing bacteria.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between Cefazolin and ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Cephalosporin Antibiotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of Cefazolin is: 1-2 g IV/IM every 6-8 hours; maximum 12 g/day.. The standard adult dose of ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER is: For uncomplicated infections: 1-2 g IV every 8 hours. For severe infections: up to 2 g IV every 4 hours. Administered as an IV infusion over 30-60 minutes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between Cefazolin and ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. Cefazolin is classified as Category A/B. Cefazolin is classified as FDA Pregnancy Category B. Animal studies have not demonstrated fetal risk, and adequate, well-controlled studies in pregnant women are lacking. Generally. ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. Pregnancy Category B. No evidence of risk in humans based on animal studies and human data; however, adequate studies in pregnant women are lacking. No known teratogenic effects in. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.